TOFA-Predict in psoriatic arthritis patients
A systems medicine approach to predict therapy response in psoriatic arthritis
A major problem in medicine is the lack of knowledge on what medicine to use. Within TOFA-Predict the partners UMC Utrecht, Pfizer and Olink exploit a novel and unprecedented systems medicine approach to identify molecular fingerprints (biomarkers) that can predict response to therapy in patients with psoriatic arthritis (PsA). In addition, novel fingerprints will be identified that predict disease progression and outcome as well as increase our understanding for disease pathology necessary to develop even more efficient treatments. Early treatment is of paramount in PsA as patients who are left untreated develop irreversible joint damage as well as co-morbidity including cardiovascular disease. More specifically, ~ 30% of the patients has developed joint damage before effective therapy is installed.
In TOFA-predict the reseachers will focus on the identification of molecular fingerprints that predict response to therapy to methotrexate, TNF inhibitors and a novel molecule tofacitinib. To this aim they will perform an ultra-deep molecular profiling using sophisticated omics approaches, various novel ways for imaging and physiological tests which will be integrated by using computational modeling and artificial intelligence.